Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 11/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 11/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.47 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383820 | 0.84 | ALDH1A1 (0.66) | SMN1; SMN2AKR1C3AKR1C2KDM4EPOLB | |
| Benzene SCHEMBL29227606 | 0.82 | ALDH1A1 (0.63) | SMN1; SMN2AKR1C3AKR1C2KDM4EPOLB | |
| SCHEMBL32665938 | 0.81 | HTT (0.54) | KDM4EALDH1A1KCNK2KCNK10TSHR | |
| SCHEMBL1950595 | 0.81 | NPC1 (0.58) | SMN1; SMN2ALDH1A1TSHRNPC1RAB9A | |
| SCHEMBL5307872 | 0.80 | NPC1 (0.63) | SMN1; SMN2AKR1C3AKR1C2KDM4EPOLB | |
| SCHEMBL27944733 | 0.80 | ALDH1A1 (0.50) | SMN1; SMN2KDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL1983309 | 0.79 | AKR1C3 (0.53) | SMN1; SMN2AKR1C3AKR1C2KDM4EPOLB | |
| SCHEMBL4128750 | 0.79 | ALDH1A1 (0.65) | SMN1; SMN2AKR1C3AKR1C2KDM4EPOLB | |
| SCHEMBL23140494 | 0.78 | SMN1; SMN2 (0.54) | SMN1; SMN2AKR1C3AKR1C2KDM4EPOLB | |
| SCHEMBL30938277 | 0.78 | SMN1; SMN2 (0.54) | SMN1; SMN2AKR1C3AKR1C2KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| WO-2007042660-A2 | SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | AGTR1, AGTR2, AHR | SMN1; SMN2 2592/4885AKR1C3 92/4885AKR1C2 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.